Related Experiment Video
Updated: Feb 9, 2026

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
Published on: January 7, 2019
CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both
1South Australian Health and Medical Research Institute, University of Adelaide, Australia.
Abstract:
Inhibitors of cholesteryl ester transfer protein (CETP) were developed due to their ability to raise HDL-C levels. Preclinical studies demonstrated favorable effects on atherosclerotic plaque with CETP inhibitory approaches in animal models. While these agents raise HDL-C and lower LDL-C, most have not proven to reduce cardiovascular event rates in large outcome trials. The state of opinion after all of these clinical trials is reviewed.
Related Concept Videos
Benefits of Self-Esteem
Cholesterol: Significance and Regulation
Considering cholesterol and...
Feedback Inhibition
Relative Risk
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Enzyme Inhibition

